Charles Schwab
DMRA

Charles Schwab’s Damora Therapeutics DMRA Stock Holding History

Charles Schwab’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.7M Buy
142,137
+129,637
+1,037% +$3.14M ﹤0.01% 2588
2026
Q1 		$324K Buy
+12,500
New +$321K ﹤0.01% 3230
2024
Q2 		– Sell
-630
Closed -$12.3K – 3649
2024
Q1 		$12.3K Hold
630
– – ﹤0.01% 3455
2023
Q4 		$11.3K Hold
630
– – ﹤0.01% 3519
2023
Q3 		$11.3K Hold
630
– – ﹤0.01% 3558
2023
Q2 		$39.7K Buy
+630
New +$34.3K ﹤0.01% 3449

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

Charles Schwab's DMRA Position: Q2 2026 in Review

Charles Schwab increased its Damora Therapeutics (DMRA) stake by 1,037% in Q2 2026, buying an estimated $3.14M and bringing the position to 142,137 shares worth $3.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2588.

Charles Schwab first reported a position in DMRA in Q2 2023 and has held it in 6 quarters since. 104 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

  • Charles Schwab held 142,137 shares of Damora Therapeutics worth $3.7M as of Q2 2026.
  • Charles Schwab bought 129,637 Damora Therapeutics shares in Q2 2026, an estimated $3.14M.
  • Damora Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2588 holding.
  • Charles Schwab first reported a position in Damora Therapeutics in Q2 2023 and has held it in 6 quarters since.
  • 104 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.